Peripheral Plasma Micro-RNA and Proteomics Mapping in Depressive Patients, Treated With SSRI Medications.
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Depression
- Sponsor
- HaEmek Medical Center, Israel
- Enrollment
- 17
- Locations
- 1
- Primary Endpoint
- Depressive symptoms remission or response rates, under usual SSRI treatment.
- Status
- Terminated
- Last Updated
- 10 years ago
Overview
Brief Summary
A pilot study of mapping the peripheral plasma micro-RNA and proteomics patterns in depressive patients, treated with SSRI medications. It is an observational clinical bio-markers laboratory controlled research with no device.
The research includes two groups; one for patients diagnosed of having depression, and will get a standard SSRI medication regimen. Second group is for control subjects without depression. An option for a third group is planned to include first degree relatives of the depressed patients. After giving their informed consents, subjects and patients will go through standard clinical psychiatric interview, and routine clinical lab tests. Clinical standard, specific depression and anxiety questionnaires will be held at four follow-up meetings: at start; after 2 weeks; 4 weeks; and 10 weeks. Subjects and patients will be asked to give blood samples at these points of time for the lab processing: Complete plasma proteomics and specific micro-RNA levels.
Investigators
Amichai Hareven
Dr Amichai Hareven
HaEmek Medical Center, Israel
Eligibility Criteria
Inclusion Criteria
- •Depressed patients,over 18 yo
- •Untreated with SSRI, in the last 3 months
Exclusion Criteria
- •Bipolar patients or another major psychopathology
- •Depressive disorder clearly due to general medical condition, or drug related
- •BMI under 18.5 or above 40
- •Pregnant patients
- •Active suicidality
Outcomes
Primary Outcomes
Depressive symptoms remission or response rates, under usual SSRI treatment.
Time Frame: 10 weeks of follow up